Showing results (11-20 of 31) with videos related to
Sort By:
Pageof 4
Bioorganic & Medicinal Chemistry Letters|October 2, 2007
Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitorsMichael P Dwyer, Kamil Paruch, Carmen Alvarez, et al.ACS Medicinal Chemistry Letters|August 22, 2018
Structure-Guided Design and Procognitive Assessment of a Potent and Selective Phosphodiesterase 2A InhibitorShawn J Stachel, Richard Berger, Ashley B Nomland, et al.Biopolymers|October 17, 2007
Structure-guided discovery of cyclin-dependent kinase inhibitorsThierry O Fischmann, Alan Hruza, José S Duca, et al.Bioorganic & Medicinal Chemistry|March 5, 2014
The identification of novel 5'-amino gemcitabine analogs as potent RRM1 inhibitorsMarc A Labroli, Michael P Dwyer, Ruichao Shen, et al.Molecular Cancer Therapeutics|July 29, 2010
Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitorDavid Parry, Timothy Guzi, Frances Shanahan, et al.Bioorganic & Medicinal Chemistry Letters|June 16, 2009
Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide regionCynthia Aki, Jianping Chao, Johan A Ferreira, et al.Bioorganic & Medicinal Chemistry Letters|February 5, 2008
Synthesis and structure-activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonistsYounong Yu, Michael P Dwyer, Jianping Chao, et al.Bioorganic & Medicinal Chemistry Letters|September 17, 2016
Alternative core development around the tetracyclic indole class of HCV NS5A inhibitorsLing Tong, Wensheng Yu, Craig A Coburn, et al.Bioorganic & Medicinal Chemistry Letters|July 11, 2016
Aryl or heteroaryl substituted aminal derivatives of HCV NS5A inhibitor MK-8742Wensheng Yu, Craig A Coburn, Anilkumar G Nair, et al.Journal of Medicinal Chemistry|December 22, 2006
Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonistMichael P Dwyer, Younong Yu, Jianping Chao, et al.Pageof 4